Case Report
Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review
Table 1
The evolution of pertinent lab results: pretreatment, during treatment, and posttreatment.
| Labs | Dates | Pretreatment | During treatment | Posttreatment | Apr-19 | Aug-19 | Dec-19 | Jan-20 | Jul-20 | Sep-20 | Jan-21 | Feb-21 | Mar-21 | Apr-21 | May-21 | Jun-21 | Aug-21 | Sep-21 |
| AST, U/L | 107 | 47 | 72 | 87 | 108 | 94 | 93 | 109 | 81 | 49 | 44 | 70 | 49 | 51 | ALT, U/L | 73 | 27 | 44 | 51 | 64 | 55 | 48 | 66 | 50 | 36 | 31 | 43 | 28 | 30 | ALP, U/L | 53 | 53 | 57 | 78 | 81 | 80 | 112 | 99 | 83 | 77 | 83 | 84 | 96 | 108 | Total bilirubin, mg/dL | 1.5 | 1 | 1.0 | 1.1 | 1.9 | 1.5 | 1.2 | 1.2 | 2.3 | 2.6 | 2.8 | 1 | 1.3 | 1.3 | PT/INR | 1.2 | 1.2 | NT | NT | NT | 1.2 | 1.1 | 1.2 | 1.2 | 1.1 | 1.1 | 1.2 | 1.2 | 1.1 | Platelets, 103/μL | 115 | 197 | 67 | 54 | 78 | 100 | 106 | 108 | 103 | 107 | 117 | 105 | 92 | 107 | Albumin, g/dL | 3.6 | 4.2 | 3.5 | 3.3 | 3.4 | 3.6 | 3.3 | 3.6 | 3.6 | 3.5 | 3.6 | 3.8 | 3.6 | 3.5 | Creatinine, mg/dL | 0.8 | 1.4 | 0.7 | 0.6 | 0.9 | 0.8 | 0.8 | 1.0 | 0.9 | 0.8 | 0.8 | 0.9 | 1.2 | 0.9 | eGFR, mL/min/1.73 m2 | >90 | 62 | 52 | >90 | 85 | 92 | 95 | 85 | 85 | 85 | 93 | 83 | 61 | 80 | Sodium, mmol/L | 136 | 137 | 136 | 135 | 135 | 134 | 134 | 135 | 136 | 135 | 138 | 135 | 136 | 136 | HCV-RNA quant (IU) | 338,000 | NT | 6,510,00 | NT | 1,550,000 | NT | NT | NT | ND | ND | ND | ND | ND | ND |
|
|
NT, not tested; ND, not detected.
|